BioSpace News Archive

Athersys, Inc. announced that its partner in Japan, HEALIOS K.K., exercised in full its warrant to purchase shares of Athersys common stock.

Myriad Genetics, Inc. announced it has submitted a supplementary application with the Japanese Ministry of Health Labour and Welfare for its BRACAnalysis® Diagnostic System to be used as a companion diagnostic to help to identify people with metastatic pancreatic or metastatic castration-resistant prostate cancer who have germline BRCA1 and BRCA2 mutations and may be candidates for targeted therapy with the PARP inhibitor, Lynparza®, subject to regulatory approval.

Microbix Biosystems Inc. announces the creation, verification, and imminent commercial availability of a quality assessment product to help ensure the accuracy of COVID-19 disease testing..

BioCryst Pharmaceuticals, Inc. announced that the European Medicines Agency has validated its marketing authorization application submission for approval of oral, once-daily berotralstat for the prevention of hereditary angioedema attacks..

Joint Venture Procures from Established Manufacturers with Reliable Supply and Logistics for US Medical Operations

Bio-Techne Corporation announced researchers from its Munich-based laboratory, Exosome Diagnostics, in a paper published in the scientific Journal of Extracellular Vesicles, showed that tumor- derived RNA was not detected in thrombocytes in samples where the tumor RNA was readily detected in exosomes.

Cigna is waiving customer cost-sharing and co-payments for COVID-19 treatment.

Alphamab Oncology announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a wholly-owned subsidiary of the Company, has established strategic partnership with Simcere and 3D Medicines Co., Ltd. to advance the development and commercialization of KN035, a checkpoint inhibitor for programmed cell death ligand-1, for oncology indications in mainland China.

LifeMax Laboratories, Inc. announced the formation of AmMax Bio, Inc. and an exclusive worldwide license from Amgen for the right to develop, manufacture and commercialize AMG 820, a monoclonal antibody against the colony-stimulating factor 1 receptor that has completed Phase I/II clinical studies in solid tumors.

Seres Therapeutics, Inc., announced that the Company has completed enrollment of its SER-109 Phase 3 clinical study, ECOSPOR III.